Study of Cognitive-Linguistic Profiles: The Role of Executive Control in Aphasia (P-CLAC)

August 10, 2026 updated by: University Hospital, Toulouse

Study of Cognitive-linguistic Profiles in Brain-injured Adults: the Role of Executive Control in Mild Aphasia.

In France, stroke affects 150,000 people annually and is the leading cause of acquired disability in adults; 10-12% of patients exhibit mild post-stroke aphasia, a condition defined by language difficulties.

Few studies describe mild post-stroke aphasia, and none characterize the impairment of linguistic executive control in this population; consequently, its prevalence remains unknown. To date, the role of linguistic executive control in mild aphasia remains an open question.

The aim of this project is to investigate linguistic executive control impairment in stroke survivors with mild aphasia, provide an initial estimate of its prevalence, and demonstrate its interactions with other linguistic and communicative aspects, as well as with executive and attentional functions.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Toulouse, France, 31300
        • Service de Médecine Physique et de Réadaptation Hôpital Raymonde Fournet Purpan
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient who has experienced a first ischemic stroke resulting in clinical symptoms within the last 3 months and is receiving care in the Physical Medicine and Rehabilitation department.
  • Score ≤ 31 on the conversational speech observation scale of the MEC test (Montreal Protocol for the Evaluation of Communication).
  • Patients with a BDAE score ≥ 3 (Boston Diagnostic Aphasia Examination - French version, Mazaux J.-M. [1990]); this score is the gold standard in aphasiology.
  • Native French-speaking patient capable of understanding oral or written instructions.

Exclusion Criteria:

  • Patients exhibiting behavior or a clinical condition incompatible with test administration, as assessed by the clinician.
  • Known major visual, auditory, or motor impairments incompatible with test performance.
  • Known neurodegenerative and/or neurodevelopmental disorders.
  • Known social cognition disorders (e.g., ASD).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients whose neuropsychological and speech-language pathology tests will be randomized
Diagnostic test: Neuropsychological tests
Patients undergo neuropsychological tests, the order of which will be randomized.
Diagnostic test: Speech-language assessments
Patients will undergo speech-language assessments, with the order of the tests randomized.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measure the proportion of patients with mild post-stroke aphasia exhibiting deficits in linguistic executive control within three months of a first stroke
Time Frame: 7 days after the inclusion
CATEX score result (deficit score if below the mean value minus 1.65 times the standard deviation)
7 days after the inclusion

Secondary Outcome Measures

Outcome Measure
Time Frame
Study of the correlation between executive control of language (CATEX score) and the score of the test evaluating access to the lexical stock
Time Frame: 7 days after the inclusion
7 days after the inclusion
Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating access to the semantic system
Time Frame: 7 days after the inclusion
7 days after the inclusion
Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating non-verbal executive control
Time Frame: 7 days after the inclusion
7 days after the inclusion
Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating gnosies
Time Frame: 7 days after the inclusion
7 days after the inclusion
Identification of patients' cognitive-linguistic impairment profiles based on cognitive test scores
Time Frame: 7 days after the inclusion
7 days after the inclusion
Identification of patients' cognitive-linguistic impairment profiles based on stroke location using factor analysis
Time Frame: 7 days after the inclusion
7 days after the inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 8, 2028

Study Registration Dates

First Submitted

July 20, 2026

First Submitted That Met QC Criteria

August 10, 2026

First Posted (Actual)

August 14, 2026

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 10, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC31/25/0614
  • ID-RCB (Other Identifier: 2025-A02583-46)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe